Zoledronic acid inhibits osteosarcoma growth in an orthotopic model, Molecular Cancer Therapeutics, vol.6, issue.12, pp.3263-70, 2007. ,
DOI : 10.1158/1535-7163.MCT-07-0546
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model, Cancer Letters, vol.274, issue.2, pp.271-78, 2009. ,
DOI : 10.1016/j.canlet.2008.09.026
SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients, European Journal of Cancer, vol.43, issue.4, pp.752-61, 2007. ,
DOI : 10.1016/j.ejca.2006.10.023
Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial, Current Oncology, vol.17, issue.6, pp.23-31, 2010. ,
DOI : 10.3747/co.v17i6.578
Discrete Sequential Boundaries for Clinical Trials, Biometrika, vol.70, issue.3, pp.659-63, 1983. ,
DOI : 10.2307/2336502
Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1, Proc Am Soc Clin Oncol, vol.33, 2015. ,
The effect of zoledronate during bone healing, Journal of Orthopaedics and Traumatology, vol.17, issue.10, pp.7-12, 2010. ,
DOI : 10.1016/j.biomaterials.2004.09.026
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet, vol.386, pp.1353-61, 2015. ,
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis, International Journal of Cancer, vol.19, issue.7, pp.1705-1714, 2009. ,
DOI : 10.1002/ijc.24470
A meta-analysis of the antitumor eff ect and safety of bisphosphonates in the treatment of multiple myeloma ,
Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors, Journal of Breast Cancer, vol.17, issue.4, pp.350-55, 2014. ,
DOI : 10.4048/jbc.2014.17.4.350
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma, Cancer, vol.467, issue.suppl 2, pp.1736-1780, 2011. ,
DOI : 10.1007/s11999-009-0912-9
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children???s Oncology Group, European Journal of Cancer, vol.49, issue.10, pp.2384-91, 2013. ,
DOI : 10.1016/j.ejca.2013.03.018
Short-term safety assessment in the use of intravenous zoledronic acid in children, The Journal of Pediatrics, vol.145, issue.5, pp.701-705, 2004. ,
DOI : 10.1016/j.jpeds.2004.06.066
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study, Pediatric Blood & Cancer, vol.78, issue.2, pp.275-82, 2011. ,
DOI : 10.1007/s002770050496
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial, The Lancet Oncology, vol.15, issue.9, pp.997-1006, 2014. ,
DOI : 10.1016/S1470-2045(14)70302-X
Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo, Clinical Cancer Research, vol.20, issue.11, pp.2922-2954, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-1246
Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases, Cancer Research, vol.70, issue.18, pp.7063-72, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-4291
Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks effi cacy against pulmonary metastases in a syngeneic rat model, Int J Cancer, vol.127, pp.345-54, 2010. ,
??/?? T-Cell Stimulation by Pamidronate, New England Journal of Medicine, vol.340, issue.9, pp.737-775, 1999. ,
DOI : 10.1056/NEJM199903043400914
Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer, Cancer Discovery, vol.5, issue.1, pp.35-42, 2015. ,
DOI : 10.1158/2159-8290.CD-14-0621
Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents, Clinical Cancer Research, vol.17, issue.8, pp.2110-2129, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2047
Zoledronic acid increases the circulating soluble RANKL level in mice, with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide, Cytokine, vol.83, pp.1-7, 2016. ,
DOI : 10.1016/j.cyto.2016.03.012